The license comprises the patent application entitled ‘Identification of Ergothioneine Transporter and Therapeutic Uses Thereof.’ This transporter is present in human cells, especially red and white blood cells, has a gene symbol SLC22A4, and can efficiently move the antioxidant L-Ergothioneine (ERGO) across cell membranes.
ERGO is a naturally occurring potent antioxidant that is abundant in most plants and animals. ERGO cannot be manufactured by humans and therefore is available only from dietary sources. Highest levels of this nutrient are found in a number of human organ systems including liver, kidney, the eye, seminal fluid, and red blood cells. It plays a dual role in both energy regulation and in protecting cells from oxidative damage.
Dr Dirk Grundemann, professor at University of Cologne and a discoverer of the ERGO transporter, said: “Supplementation of ERGO to correct a dietary deficit could provide a new therapeutic strategy for chronic inflammatory diseases.”
Marvin Hausman, CEO of TNS, said: “The acquisition of the ERGO transporter license is further evidence of the role of TNS as a global leader in the research and development of mushrooms and their contained potent antioxidants and bionutrients. ERGO may finally be recognized as a new important vitamin with a key role in protecting human cells and tissues against the ravages of many diseases.
“TNS has positioned itself as a global leader in the research and development of natural organic whole food dietary supplements, with increased concentrations of needed antioxidants such as ERGO and Vitamin D. The company has also taken on the mission to educate people with the concept of proper whole food nutrition based on Prevention, Not Intervention.”